glp-1 dpp 4 Frontiers GLP 1 Receptor Agonists and

These include cardiovascular protection, neuroprotection, and metabolic regulation, which can influence conditions such as polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and osteoporosis

Many patients with type 2 diabetes notice better blood glucose control within the first 12 weeks of starting treatment, even at initial lower doses

It also targets other cells in the pancreas to stop the glucagon signal for generating glucose in the liver.[ref] In clinical trials, GLP-1 RAs improved lipid profiles, increased satiety, slowed gastric emptying, reduced inflammation, and had neuroprotective effects.[ref] The slowing of gastric emptying and reducing inflammation may play a role in weight loss, along with the decrease in appetite and eating less

Clinically defined and diagnosed as having a body mass index (BMI) exceeding 30 kg/m 2 , the condition has rapidly risen in the global human population from 4% in 1975 to an astounding 18% (more than quadruple) in 2016

ci thin tnh n nh ca GLP-1, cc nh nghin cu thng s dng nhiu phng php khc nhau ci thin n, chng hn nh sa i ha hc v iu chnh cu trc phn t